share_log

Despite Delivering Investors Losses of 55% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

Despite Delivering Investors Losses of 55% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

儘管在過去3年中給投資者帶來了55%的損失,但微科技(南京)有限公司(上海證券交易所代碼:688029)的收益一直在增長
Simply Wall St ·  12/11 19:22

Micro-Tech (Nanjing) Co.,Ltd (SHSE:688029) shareholders should be happy to see the share price up 19% in the last quarter. But over the last three years we've seen a quite serious decline. Tragically, the share price declined 57% in that time. So it's good to see it climbing back up. After all, could be that the fall was overdone.

南微醫學(南京)有限公司(上海證券交易所代碼:688029)的股東們應該高興地看到股價在上個季度上漲了19%。但是在過去的三年中,我們看到了一定程度的下滑。遺憾的是,股價在這段時間內下跌了57%。所以看到它再次回升是件好事。畢竟,這可能是跌幅過度。

The recent uptick of 3.2% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上漲了3.2%可能是未來的積極信號,所以讓我們來看看歷史數據。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然一些人仍然教授有效市場假說,但已經證明市場是過於反應的動態系統,投資者並不總是理性。一個不完美但簡單的考慮市場對公司認知變化的方法是,將每股收益(EPS)的變化與股價波動進行比較。

Although the share price is down over three years, Micro-Tech (Nanjing)Ltd actually managed to grow EPS by 22% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.

雖然股價在過去三年裏下跌,但南微醫學(南京)有限公司實際上在此期間每年的每股收益增長了22%。考慮到股價的反應,人們可能會懷疑每股收益並不是這段時間內業務表現的良好指標(可能是由於一次性損失或收益)。或者說,公司曾經被過度炒作,因此其增長令人失望。

It's worth taking a look at other metrics, because the EPS growth doesn't seem to match with the falling share price.

值得看看其他指標,因爲每股收益的增長似乎與股價下跌不匹配。

The modest 1.4% dividend yield is unlikely to be guiding the market view of the stock. We note that, in three years, revenue has actually grown at a 12% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Micro-Tech (Nanjing)Ltd further; while we may be missing something on this analysis, there might also be an opportunity.

適度的1.4%的分紅派息收益率不太可能指導市場對該股票的看法。我們注意到,在三年內,營業收入實際上以每年12%的速度增長,因此這似乎不是賣出股票的理由。可能值得進一步調查南微醫學(南京)有限公司;雖然我們在這項分析中可能錯過了什麼,但也可能存在機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面查看盈餘和營業收入隨着時間的變化(通過點擊圖像發現具體數值)。

big
SHSE:688029 Earnings and Revenue Growth December 12th 2024
SHSE:688029 每股收益和營業收入增長 2024年12月12日

We know that Micro-Tech (Nanjing)Ltd has improved its bottom line lately, but what does the future have in store? So we recommend checking out this free report showing consensus forecasts

我們知道南微醫學(南京)有限公司最近改善了其盈利能力,但未來將會怎樣呢?因此,我們建議查看這份顯示共識預測的免費報告。

A Different Perspective

不同的視角

While the broader market gained around 12% in the last year, Micro-Tech (Nanjing)Ltd shareholders lost 24% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Micro-Tech (Nanjing)Ltd .

儘管更廣泛的市場在去年增長了約12%,但南微醫學(南京)有限公司的股東虧損了24%(即使包括分紅派息)。然而,請記住,即使是最佳股票在十二個月期間也會表現不佳。不幸的是,去年的表現可能表明存在未解決的挑戰,因爲其表現遜色於過去五年年化損失的6%。一般而言,長期股價疲軟可能是一個不好的跡象,儘管逆勢投資者可能希望研究該股票,以期實現反彈。我發現觀察長期股價作爲業務表現的代理非常有趣。但要真正獲得洞察力,我們還需要考慮其他信息。爲此,你應該注意我們發現的南微醫學(南京)有限公司的一個警告信號。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果你像我一樣,那麼你一定不想錯過這份內部人士正在購買的被低估的小型股免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論